Viridian Therapeutics, Inc. (VRDN) Stock Ticker
VRDN right now
Market factors today
Unlock the full VRDN picture
About Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
VRDN stock facts
| Ticker symbol | VRDN |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $2.3B |
| CEO | Stephen F. Mahoney |
| Employees | 252 |
| Headquarters | Waltham, MA, US |
| IPO date | 2014-06-18 |
| Website | www.viridiantherapeutics.com |
What you can see for VRDN on Tickr
Live VRDN price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the VRDN report.
Rankings
FAQ
What is the ticker symbol for Viridian Therapeutics, Inc.?
The ticker symbol for Viridian Therapeutics, Inc. is VRDN, listed on the NASDAQ Capital Market.
What is VRDN?
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1…